BRPI0507462A - compostos de quinolina substituìdos - Google Patents

compostos de quinolina substituìdos

Info

Publication number
BRPI0507462A
BRPI0507462A BRPI0507462-2A BRPI0507462A BRPI0507462A BR PI0507462 A BRPI0507462 A BR PI0507462A BR PI0507462 A BRPI0507462 A BR PI0507462A BR PI0507462 A BRPI0507462 A BR PI0507462A
Authority
BR
Brazil
Prior art keywords
compounds
quinoline compounds
substituted quinoline
compositions
mtp
Prior art date
Application number
BRPI0507462-2A
Other languages
English (en)
Inventor
Peter Bertinato
Michel Andre Couturier
Ernest Seiichi Hamanaka
Marcus Douglas Ewing
Ralph Pelton Robinson Jr
Derek Lawrence Tickner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0507462A publication Critical patent/BRPI0507462A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

COMPOSTOS DE QUINOLINA SUBSTITUìDOS. A presente invenção refere-se aos inibidores de secreção MTP/Apo-B de fórmula (l) em que R¬ 1¬ -R¬ 7¬, X¬ 1¬, m e n são como definidos no relatório, assim como as composições farmacêuticas compreendendo os compostos, e métodos de uso dos compostos e composições. Os compostos da invenção são utilizá-veis no tratamento de obesidade e doenças, condições ou distúrbios associados.
BRPI0507462-2A 2004-02-04 2005-01-24 compostos de quinolina substituìdos BRPI0507462A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54167804P 2004-02-04 2004-02-04
US63376304P 2004-12-06 2004-12-06
PCT/IB2005/000167 WO2005080373A1 (en) 2004-02-04 2005-01-24 Substituted quinoline compounds

Publications (1)

Publication Number Publication Date
BRPI0507462A true BRPI0507462A (pt) 2007-07-10

Family

ID=34890449

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507462-2A BRPI0507462A (pt) 2004-02-04 2005-01-24 compostos de quinolina substituìdos

Country Status (25)

Country Link
US (3) US7468378B2 (pt)
EP (1) EP1716137A1 (pt)
JP (1) JP2007520543A (pt)
KR (1) KR100799802B1 (pt)
AP (1) AP2006003685A0 (pt)
AR (1) AR047529A1 (pt)
AU (1) AU2005214159A1 (pt)
BR (1) BRPI0507462A (pt)
CA (1) CA2555133A1 (pt)
CO (1) CO5700721A2 (pt)
CR (1) CR8544A (pt)
EA (1) EA010369B1 (pt)
EC (1) ECSP066717A (pt)
GE (1) GEP20084360B (pt)
IL (2) IL176715A0 (pt)
MA (1) MA28347A1 (pt)
NL (1) NL1028192C2 (pt)
NO (1) NO20063928L (pt)
OA (1) OA13365A (pt)
PA (1) PA8623001A1 (pt)
PE (1) PE20050773A1 (pt)
SV (1) SV2007002007A (pt)
TW (2) TWI306454B (pt)
UY (1) UY28734A1 (pt)
WO (1) WO2005080373A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
GEP20084360B (en) * 2004-02-04 2008-04-29 Pfizer Prod Inc Substituted quinoline compounds
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
WO2005100325A1 (en) * 2004-04-14 2005-10-27 Astrazeneca Ab Aryl glycinamide derivatives and their use as nk1 antagonists and serotonin reuptake inhibithors
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
EA024768B1 (ru) * 2005-04-19 2016-10-31 Сюрфэйс Лоджикс, Инк. Ингибиторы белка микросомального транспорта триглицеридов и секреции апо-в
EP2222631B1 (en) * 2006-10-23 2011-08-17 Pfizer Inc. Substituted phenylmethyl bicyclocarboxyamide compounds
MX2009004314A (es) 2006-11-13 2009-05-05 Pfizer Prod Inc Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos.
WO2008097471A1 (en) * 2007-02-02 2008-08-14 Shivvers Steve D High efficiency drier with multi stage heating and drying zones
WO2008100423A1 (en) * 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
WO2009014674A1 (en) * 2007-07-23 2009-01-29 Sirtris Pharmaceuticals, Inc. Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors
ES2748136T3 (es) 2007-10-15 2020-03-13 United Animal Health Inc Método para aumentar el rendimiento de las crías
ES2630406T3 (es) * 2007-10-19 2017-08-21 Sarcode Bioscience Inc. Composición y procedimientos para el tratamiento de la retinopatía diabética
WO2010018547A1 (en) * 2008-08-13 2010-02-18 Pfizer Inc. Aminoquinoline compounds
EP2723718A1 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
US8710043B2 (en) 2011-06-24 2014-04-29 Amgen Inc. TRPM8 antagonists and their use in treatments
JP6097289B2 (ja) * 2011-08-04 2017-03-15 アレイ バイオファーマ、インコーポレイテッド セリン／スレオニンキナーゼインヒビターとしてのキナゾリン化合物
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
US9624172B2 (en) 2014-02-17 2017-04-18 Hetero Research Foundation Polymorphs of lomitapide and its salts
MA41051B1 (fr) 2014-10-06 2020-11-30 Vertex Pharma Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
WO2016055934A1 (en) * 2014-10-09 2016-04-14 Glenmark Pharmaceuticals Limited Amorphous form of lomitapide mesylate
CA3019380A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN109803962B (zh) 2016-09-30 2022-04-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物
MD3551622T2 (ro) 2016-12-09 2021-03-31 Vertex Pharma Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
JP6906105B2 (ja) * 2017-06-16 2021-07-21 成都先導薬物開発股▲ふん▼有限公司Ｈｉｔｇｅｎ Ｌｔｄ． Ｒｏｃｋを阻害する化合物及びその使用
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
JP7121794B2 (ja) 2017-08-02 2022-08-18 バーテックス ファーマシューティカルズ インコーポレイテッド ピロリジン化合物を調製するためのプロセス
WO2019079760A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
EP3720849A2 (en) 2017-12-08 2020-10-14 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2819039A1 (de) 1978-04-29 1979-11-08 Bayer Ag Leimungsmittel fuer papier
HU189569B (en) 1981-03-11 1986-07-28 The Wellcome Foudation Ltd,Gb Process for preparing 2-substituted phenyl/-benzoic acids and pharmaceutical compositons containing such compounds as active substances
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
CA2091102C (en) 1992-03-06 2009-05-26 John R. Ii Wetterau Microsomal triglyceride transfer protein
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DK0804419T3 (da) 1994-05-27 2003-11-24 Glaxosmithkline Spa Quinolinderivater som tachykinin NK 3-receptor-antagonister
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE19519245C2 (de) * 1995-04-14 2003-04-30 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
WO1996040640A1 (en) 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
ATE233734T1 (de) 1995-06-07 2003-03-15 Pfizer Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6 yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
EP0952832B1 (en) * 1996-05-20 2008-08-27 Darwin Discovery Limited Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors
JP2000515501A (ja) 1996-07-01 2000-11-21 イーライ・リリー・アンド・カンパニー 低血糖化および低脂血化用化合物群
KR100217618B1 (ko) * 1996-12-12 1999-09-01 정몽규 와셔액 분사위치 조절 장치
WO1998027979A1 (en) 1996-12-20 1998-07-02 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US5968950A (en) 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
AP1201A (en) 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
DE69831506T2 (de) * 1997-12-22 2006-06-29 Pharmacia & Upjohn Co. Llc, Kalamazoo 4-hydroxychinolin-3-carboxamide und hydrazide als antivirale wirkstoffe
CO5090829A1 (es) 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
CO5271688A1 (es) 1999-11-10 2003-04-30 Pfizer Prod Inc Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
US20020032238A1 (en) * 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
US6417367B1 (en) * 2000-08-11 2002-07-09 Pfizer Inc. Methods of making quinoline amides
PL362546A1 (en) 2000-10-05 2004-11-02 Fujisawa Pharmaceutical Co, Ltd. Benzamide compounds as apo b secretion inhibitors
SK287806B6 (sk) 2001-06-28 2011-10-04 Pfizer Products Inc. Triamid-substituované indoly, benzofurány a benzotiofény ako inhibítory mikrozómového proteínu prenášajúceho triglyceridu (MTP) a/alebo sekrécie apolipoproteínu B (Apo B)
US7183415B2 (en) 2001-10-25 2007-02-27 Takeda Pharmaceutical Company Limited Quinoline compound
JP2005511713A (ja) * 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 加齢性黄斑変性についての処置
US20030162788A1 (en) * 2002-01-10 2003-08-28 Boehringer Ingelheim Pharma Kg Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals
BR0306292A (pt) 2002-02-28 2004-08-24 Japan Tobacco Inc Composto de éster e uso medicinal do mesmo
WO2004056775A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
EP1578725A1 (en) * 2002-12-20 2005-09-28 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
GEP20084360B (en) * 2004-02-04 2008-04-29 Pfizer Prod Inc Substituted quinoline compounds

Also Published As

Publication number Publication date
EA200601239A1 (ru) 2007-02-27
NL1028192C2 (nl) 2006-05-30
US7468378B2 (en) 2008-12-23
SV2007002007A (es) 2007-03-20
PA8623001A1 (es) 2006-03-24
GEP20084360B (en) 2008-04-29
EP1716137A1 (en) 2006-11-02
ECSP066717A (es) 2006-10-31
KR20060127123A (ko) 2006-12-11
AU2005214159A1 (en) 2005-09-01
MA28347A1 (fr) 2006-12-01
JP2007520543A (ja) 2007-07-26
AP2006003685A0 (en) 2006-08-31
NL1028192A1 (nl) 2005-08-08
AR047529A1 (es) 2006-01-25
EA010369B1 (ru) 2008-08-29
US7393958B2 (en) 2008-07-01
UY28734A1 (es) 2005-09-30
PE20050773A1 (es) 2005-10-26
NO20063928L (no) 2006-10-31
CO5700721A2 (es) 2006-11-30
OA13365A (en) 2007-04-13
US7368573B2 (en) 2008-05-06
KR100799802B1 (ko) 2008-01-31
WO2005080373A1 (en) 2005-09-01
CR8544A (es) 2006-11-30
TWI306454B (en) 2009-02-21
US20050234099A1 (en) 2005-10-20
CA2555133A1 (en) 2005-09-01
IL208963A0 (en) 2011-07-31
TW200533354A (en) 2005-10-16
TW200906800A (en) 2009-02-16
US20070093525A1 (en) 2007-04-26
US20060223851A1 (en) 2006-10-05
IL176715A0 (en) 2006-10-31

Similar Documents

Publication Publication Date Title
BRPI0507462A (pt) compostos de quinolina substituìdos
BRPI0514841A (pt) inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BRPI0512938A (pt) derivados da quinazolinediona como inibidores parp
BRPI0411721A (pt) derivados de tiazolilpiperidina como inibidores de mtp
BRPI0407454A (pt) Pirazóis e métodos de preparar e usar os mesmos
BRPI0418102A (pt) derivados de quinolina
BR0308967A (pt) Derivados de quinolina e isoquinolina, um processo para a sua preparação e sua aplicação como inibidores de inflamação
EA200802213A1 (ru) Способы лечения заболеваний крови
BRPI0510453A (pt) composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
BRPI0513901A (pt) derivados de uréia cìclicos substituìdos, preparação dos mesmos e uso farmacêutico dos mesmos como inibidores de cinase
CY1109842T1 (el) Αναστολεις της αφυδρογονασης 11-β-υδροξυστεροειδων i
BRPI0417708A (pt) derivados organofosfóricos dos indazóis e sua utilização como inibidores das proteìnas quinases
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
EA200802054A1 (ru) Ингибиторы фермента
BRPI0113162B8 (pt) compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
BRPI0514133A (pt) compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
BRPI0506477A (pt) compostos farmaceuticamente úteis e inovadores
HRP20050103A2 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6 ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.